Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11504186 | 0.91 | MCL1 (0.58) | MCL1L3MBTL1ALDH1A1LMNAHPGD | |
| SCHEMBL15464936 | 0.86 | MCL1 (0.51) | MCL1L3MBTL1ALDH1A1LMNAHPGD | |
| SCHEMBL15464354 | 0.83 | LMNA (0.51) | MCL1ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL3191411 | 0.81 | ALDH1A1 (0.63) | MCL1ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL15464255 | 0.81 | ALDH1A1 (0.50) | MCL1L3MBTL1ALDH1A1LMNAHPGD | |
| SCHEMBL16503434 | 0.81 | MCL1 (0.68) | MCL1L3MBTL1LMNAHPGDTSHR | |
| SCHEMBL3731595 | 0.79 | L3MBTL1 (0.67) | MCL1L3MBTL1LMNAHPGDTSHR | |
| SCHEMBL15261631 | 0.79 | ALDH1A1 (0.52) | MCL1ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL11504215 | 0.79 | ALDH1A1 (0.49) | MCL1L3MBTL1ALDH1A1LMNAHPGD | |
| SCHEMBL3723832 | 0.79 | L3MBTL1 (0.66) | MCL1L3MBTL1HPGDTSHRMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014022528-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019186-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | MCL1 4479/4885L3MBTL1 4256/4885ALDH1A1 3081/4885 |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | MCL1 4479/4885L3MBTL1 4256/4885ALDH1A1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.